|curasan AG -- Germany Stock|| |
EUR 1.05 0.01 0.96%
President CEO, General Counsel, Director
Mr. I. Richard Garr J.D. is Director of the Company. He is no longer Chief Financial Officer of the Company. effective May 18 2015. Mr. Garr was previously an attorney with Beli Weil Jacobs the BG Companies and Circle Management Companies. Mr. Garr is a graduate of Drew University and the Columbus School of Law The Catholic University of America . Additionally he was a founder and current Board Trustee of the First Star Foundation a childrens charity focused on abused childrens issues a founder of The Starlight Foundation Mid Atlantic chapter which focuses on helping seriously ill children and is a past Honorary Chairman of the Brain Tumor Society.
Age: 61 CEO Since 2016
49 6027 40 900 51 http://www.curasan.de
The company has return on total asset (ROA)
of (15.5) %
which means that it has lost $15.5 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (39.32) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 695 K in total debt with debt to equity ratio (D/E) of 10.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. curasan AG has Current Ratio of 1.18 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.
|Found 1 records|
|Liam Condon||Bayer Aktiengesellschaft|
curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company was founded in 1988 and is based in Kleinostheim, Germany. curasan AG operates under Healthcare Products classification in Germany and traded on Frankfurt Stock Exchange. It employs 36 people.curasan AG (CUR) is traded on Frankfurt Stock Exchange in Germany. It is located in Lindigstrasse 4 and employs 36 people.